These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 33979259)

  • 21. Clinically relevant radioresistant rhabdomyosarcoma cell lines: functional, molecular and immune-related characterization.
    Petragnano F; Pietrantoni I; Camero S; Codenotti S; Milazzo L; Vulcano F; Macioce G; Giordani I; Tini P; Cheleschi S; Gravina GL; Festuccia C; Rossetti A; Delle Monache S; Ordinelli A; Ciccarelli C; Mauro A; Barbara B; Antinozzi C; Schiavetti A; Maggio R; Di Luigi L; Polimeni A; Marchese C; Tombolini V; Fanzani A; Bernabò N; Megiorni F; Marampon F
    J Biomed Sci; 2020 Aug; 27(1):90. PubMed ID: 32854690
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Constitutive activation of MET signaling impairs myogenic differentiation of rhabdomyosarcoma and promotes its development and progression.
    Skrzypek K; Kusienicka A; Szewczyk B; Adamus T; Lukasiewicz E; Miekus K; Majka M
    Oncotarget; 2015 Oct; 6(31):31378-98. PubMed ID: 26384300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The synthetic retinoid ST1926 as a novel therapeutic agent in rhabdomyosarcoma.
    Basma H; Ghayad SE; Rammal G; Mancinelli A; Harajly M; Ghamloush F; Dweik L; El-Eit R; Zalzali H; Rabeh W; Pisano C; Darwiche N; Saab R
    Int J Cancer; 2016 Mar; 138(6):1528-37. PubMed ID: 26453552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: a rational choice.
    van Gaal JC; Roeffen MH; Flucke UE; van der Laak JA; van der Heijden G; de Bont ES; Suurmeijer AJ; Versleijen-Jonkers YM; van der Graaf WT
    Eur J Cancer; 2013 Nov; 49(16):3462-70. PubMed ID: 23867124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Retinoic acid fails to induce cell cycle arrest with myogenic differentiation in rhabdomyosarcoma.
    Al-Tahan A; Sarkis O; Harajly M; Baghdadi OK; Zibara K; Boulos F; Dighe D; Kregel S; Bazarbachi A; El-Sabban M; Skapek SX; Saab R
    Pediatr Blood Cancer; 2012 Jun; 58(6):877-84. PubMed ID: 21755593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulating the dose-rate differently affects the responsiveness of human epithelial prostate- and mesenchymal rhabdomyosarcoma-cancer cell line to radiation.
    Petragnano F; Pietrantoni I; Di Nisio V; Fasciani I; Del Fattore A; Capalbo C; Cheleschi S; Tini P; Orelli S; Codenotti S; Mazzei MA; D'Ermo G; Pannitteri G; Tombolini M; De Cesaris P; Riccioli A; Filippini A; Milazzo L; Vulcano F; Fanzani A; Maggio R; Marampon F; Tombolini V
    Int J Radiat Biol; 2020 Jun; 96(6):823-835. PubMed ID: 32149569
    [No Abstract]   [Full Text] [Related]  

  • 27. Romidepsin (FK228), a potent histone deacetylase inhibitor, induces apoptosis through the generation of hydrogen peroxide.
    Mizutani H; Hiraku Y; Tada-Oikawa S; Murata M; Ikemura K; Iwamoto T; Kagawa Y; Okuda M; Kawanishi S
    Cancer Sci; 2010 Oct; 101(10):2214-9. PubMed ID: 20624163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells.
    Yu XD; Wang SY; Chen GA; Hou CM; Zhao M; Hong JA; Nguyen DM; Schrump DS
    Cancer J; 2007; 13(2):105-13. PubMed ID: 17476138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors.
    Saijo K; Imamura J; Narita K; Oda A; Shimodaira H; Katoh T; Ishioka C
    Cancer Sci; 2015 Feb; 106(2):208-15. PubMed ID: 25492515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Romidepsin (FK228) improves the survival of allogeneic skin grafts through downregulating the production of donor-specific antibody via suppressing the IRE1α-XBP1 pathway.
    Guo Y; Song S; DU X; Tian L; Zhang M; Zhou H; Chen ZK; Chang S
    J Zhejiang Univ Sci B; 2022 May; 23(5):392-406. PubMed ID: 35557040
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of FK228, a novel histone deacetylase inhibitor, on human lymphoma U-937 cells in vitro and in vivo.
    Sasakawa Y; Naoe Y; Inoue T; Sasakawa T; Matsuo M; Manda T; Mutoh S
    Biochem Pharmacol; 2002 Oct; 64(7):1079-90. PubMed ID: 12234611
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Romidepsin (FK228), A Histone Deacetylase Inhibitor and its Analogues in Cancer Chemotherapy.
    Pojani E; Barlocco D
    Curr Med Chem; 2021; 28(7):1290-1303. PubMed ID: 32013816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SCCOHT tumors acquire chemoresistance and protection by interacting mesenchymal stroma/stem cells within the tumor microenvironment.
    Otte A; Yang Y; von der Ohe J; Melzer C; Hillemanns P; Feuerhake F; Hass R
    Int J Oncol; 2016 Dec; 49(6):2453-2463. PubMed ID: 27748897
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imatinib mesylate potentiates topotecan antitumor activity in rhabdomyosarcoma preclinical models.
    McDowell HP; Meco D; Riccardi A; Tanno B; Berardi AC; Raschellà G; Riccardi R; Dominici C
    Int J Cancer; 2007 Mar; 120(5):1141-9. PubMed ID: 17131346
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoresistance to depsipeptide FK228 [(E)-(1S,4S,10S,21R)-7-[(Z)-ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8,7,6]-tricos-16-ene-3,6,9,22-pentanone] is mediated by reversible MDR1 induction in human cancer cell lines.
    Xiao JJ; Huang Y; Dai Z; Sadée W; Chen J; Liu S; Marcucci G; Byrd J; Covey JM; Wright J; Grever M; Chan KK
    J Pharmacol Exp Ther; 2005 Jul; 314(1):467-75. PubMed ID: 15833893
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
    Barlow JW; Wiley JC; Mous M; Narendran A; Gee MF; Goldberg M; Sexsmith E; Malkin D
    Pediatr Blood Cancer; 2006 Nov; 47(6):773-84. PubMed ID: 16283617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. p21WAF1 expression induced by MEK/ERK pathway activation or inhibition correlates with growth arrest, myogenic differentiation and onco-phenotype reversal in rhabdomyosarcoma cells.
    Ciccarelli C; Marampon F; Scoglio A; Mauro A; Giacinti C; De Cesaris P; Zani BM
    Mol Cancer; 2005 Dec; 4():41. PubMed ID: 16351709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitor FK228 activates tumor suppressor Prdx1 with apoptosis induction in esophageal cancer cells.
    Hoshino I; Matsubara H; Hanari N; Mori M; Nishimori T; Yoneyama Y; Akutsu Y; Sakata H; Matsushita K; Seki N; Ochiai T
    Clin Cancer Res; 2005 Nov; 11(21):7945-52. PubMed ID: 16278420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of autophagy in malignant rhabdoid tumor cells by the histone deacetylase inhibitor FK228 through AIF translocation.
    Watanabe M; Adachi S; Matsubara H; Imai T; Yui Y; Mizushima Y; Hiraumi Y; Watanabe K; Kamitsuji Y; Toyokuni SY; Hosoi H; Sugimoto T; Toguchida J; Nakahata T
    Int J Cancer; 2009 Jan; 124(1):55-67. PubMed ID: 18821579
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.
    Olanich ME; Sun W; Hewitt SM; Abdullaev Z; Pack SD; Barr FG
    Clin Cancer Res; 2015 Nov; 21(21):4947-59. PubMed ID: 25810375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.